26
|
Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Saad F, Yardley D, Maroto P, Ke C, Jun S. 3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71134-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
27
|
Vadhan-Raj S, Henry DH, von Moos R, Hungria V, Goldwasser F, Scagliotti G, Wang J, Jun S, Dansey RD, Yeh H. Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Lipton A, Stopeck A, von Moos R, Henry DH, Richardson GE, Rodriguez GI, Bourgeois HP, Ke C, Jun S, Dansey RD. A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Henry DH, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Wang J, Jun S, Dansey RD, Yeh H. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9133] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72055-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9520 Background: Hormone ablation therapies, including adjuvant aromatase inhibitor (AI) therapy and androgen deprivation therapy (ADT), improve recurrence-free survival in patients (pts) with BC and PC, respectively. However, these treatments increase bone resorption, leading to bone loss and fractures. RANKL is a key mediator of osteoclast-mediated bone resorption. In this 24 month (mo) comparison, we investigated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preserving BMD across both populations. Methods: Two trials were conducted: a 24-mo BC study and a 36-mo PC study. Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos. All pts in both studies were prescribed calcium and vitamin D supplements. The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study. Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies. Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints). The actual numbers randomized were 252 and 1468, respectively. Results: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ). In both studies, differences between denosumab and placebo at each skeletal site were consistent, and the effects of denosumab were statistically significantly different from placebo as early as 1 month at the LS in both studies. The overall safety profile was similar to placebo in each study. Conclusions: Denosumab consistently increased BMD at all 3 skeletal sites compared with placebo in both women with BC undergoing AI therapy and in men with PC undergoing ADT. [Table: see text] [Table: see text]
Collapse
|
32
|
Chae Y, Kim J, Sohn S, Kim S, Lee S, Moon J, Jeon S, Cho Y, Choi G, Jun S. RIPK1 gene polymorphism as a prognostic marker for survival in patients with colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15078 Background: Since apoptosis plays a key role in cancer progression, we hypothesized that single nucleotide polymorphisms (SNPs) of apoptosis-related gene can affect survival after curative resection in patients with colorectal cancer. Patients and Methods: Three hundred and ninety seven patients with colorectal cancer who underwent surgery with curative intent were enrolled in the present study. The genomic DNA was extracted from fresh colorectal mucosal tissue, and the 19 SNPs of 15 apoptosis-related genes (CASP3, CASP6–10, FAS, FAS ligand [FASLG], TNSFR1A, TNSFR10B, RIPK1, BCL2, BCL2 ligand [BCL2L], TP53, and PTGS2) were determined using a PCR-RFLP assay. Results: The median age of the patients was 63 years (range, 21–85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer. Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%). Multivariate survival analysis including pathologic stage, differentiation, age, and CEA level showed that relapse-free survival for the patients with the GA+AA genotype of RIPK1 (Receptor interacting serine/threonine kinase 1) +83G>A (rs2272990) was worse than for the patients with the GG genotype (hazard ratio [HR]=1.66, 95% confidence interval [CI]=1.03–2.68, p=0.038). However, no associations were observed between the polymorphisms and overall survival (OS) in a multivariate analysis. Conclusions: RIPK1 gene polymorphism can be considered as a possible prognostic marker for survival after curative resection in patient with colorectal cancer. No significant financial relationships to disclose.
Collapse
|
33
|
Thomas DM, Chawla S, Skubitz K, Staddon A, Henshaw R, Blay J, Smith J, Ye Z, Roudier M, Jun S. Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10510] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10510 Background: GCT of bone is a primary osteolytic bone tumor with low metastatic potential that is associated with significant skeletal morbidity. GCT is rich in stromal cells that express RANKL, a key mediator of osteoclast activation. In this open-label, study, we investigated whether denosumab, a fully human monoclonal antibody against RANKL, could have a potential therapeutic effect on giant cell histology for patients with GCT. Methods: In this single-arm study, 37 patients with measurable or unresectable GCT received denosumab 120 mg subcutaneously once monthly with loading doses on days 8 and 15 of month 1. The primary endpoint was the proportion of patients with a tumor response (≥90% elimination of giant cells or no radiographic progression of the target lesion) at week 25 as assessed by histology and CT or MRI. A sample size of 35 patients was planned. All 37 enrolled patients were evaluated for safety; 35 were eligible for efficacy evaluation (2 had insufficient histology or radiology data). Results: Thirty of 35 patients (86%; 95% CI 70%-95%) had a tumor response: 20 of 20 by histology and 10 of 15 by radiology. Of 31 patients with data for assessments of clinical benefit, 26 (84%%; 95% CI 66%-95%) reported reduced pain or improvement in functional status. Bone repair was reported in 9 patients (29%; 95% CI 14%-48%). Suppression of the bone turnover markers urinary N-telopeptide and serum C-telopeptide was seen as early as 28 days after the first dose and sustained for the duration of the study. Adverse events (AEs) were reported in 33 patients (89%). One death due to surgical complications (not treatment-related) occurred on-study. No patient experienced treatment-related serious AEs or developed anti-denosumab antibodies. Conclusions: In this study, 86% of patients with measurable or unresectable GCT experienced a tumor response with denosumab. Further clinical trials of denosumab as a new therapy for GCT are warranted. [Table: see text]
Collapse
|
34
|
Gralow J, Lipton A, Fizazi K, Gao G, Jun S, Yeh H. Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1155
Background: Patients with breast cancer-induced bone disease and elevated urine-N-telopeptide (uNTx), a marker of bone resorption, are at increased risk for skeletal complications, disease progression, and death. Receptor activator of NF-kB ligand (RANKL) mediates osteoclastic bone resorption. Denosumab, a fully human monoclonal antibody, inhibits bone destruction by binding and neutralizing RANKL. Denosumab efficacy and safety were assessed in a phase 2, randomized, open-label, active-controlled trial in patients with bone metastases and elevated levels of uNTx after at least 8 weeks of intravenous (IV) bisphosphonate (BP) therapy. We report results in a subset of patients with breast cancer.
 Methods: Cancer patients with bone metastases and uNTx >50 nM/mM creatinine [Cr] following at least 8 weeks of IV BP therapy were randomized to continue IV BP therapy every 4 weeks (Q4W) or switch to subcutaneous (SC) denosumab injection (180 mg) Q4W or every 12 weeks (Q12W). The primary endpoint was the proportion of patients who achieved uNTx <50 nM/mM at week 13. Safety was also assessed.
 Results: The study population (N = 111) included 46 patients (41%) with breast cancer; the median time since diagnosis of bone metastases was approximately 1 year in both groups. At week 13, 76% of denosumab-treated patients and 33% of IV BP-treated patients had uNTx < 50 nM/mM. Denosumab-induced suppression of uNTx was rapid (as early as 2 weeks after initial treatment), sustained through week 25, and unaffected by baseline uNTx (Table). In the total study population, adverse events of grade 3, 4, or 5 were reported in 25 (71%) IV BP-treated patients and 40 (55%) denosumab-treated patients.
 
 Discussion: Denosumab reduced bone turnover in breast cancer patients with bone metastases and elevated uNTx despite prior IV BP therapy. Phase 3 trials of denosumab in cancer patients with bone metastases are in progress.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1155.
Collapse
|
35
|
Shim J, Cho I, Khurana H, Li Q, Jun S. Attenuated Total Reflectance–Fourier Transform Infrared Spectroscopy Coupled with Multivariate Analysis for Measurement of Acesulfame-K in Diet Foods. J Food Sci 2008; 73:C426-31. [DOI: 10.1111/j.1750-3841.2008.00751.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Ellis GK, Bone HG, Chlebowski RT, Paul D, Spadafora S, Smith J, Fan M, Jun S. Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Fizazi K, Lipton A, Mariette X, Suarez T, Body J, Rahim Y, Gralow JR, Gao G, Wu L, Jun S. Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3596] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Thomas D, Chawla SP, Skubitz K, Staddon AP, Henshaw R, Blay JY, Smith J, Ye Z, Roudier M, Jun S. Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10500] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Chae Y, Kim J, Sohn S, Moon J, Kim S, Ryoo H, Bae S, Choi G, Jun S, Lee M. Prognostic impact of apoptosis-related and DNA repair gene polymorphisms in patients with advanced colorectal cancer treated with capecitabine and oxaliplatin chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Lage M, Harrison DJ, Barber B, Jun S. Burden of hospitalizations associated with skeletal related events in patients with breast cancer or lung cancer and bone metastases or multiple myeloma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17083 Background: Patients with bone metastases secondary to cancer often experience skeletal related events (SREs) including pathological fracture, spinal cord compression, hypercalcemia, bone surgery or radiotherapy, or initiation of opioid analgesic use. These SREs result in major morbidity and reduced quality of life. This research examines hospitalizations associated with SREs. Methods: Data for this study were obtained from i3 LabRx Database (05/01/2000 to 03/31/2005). Individuals were included in the analyses if they had at least two diagnoses of breast cancer (based upon an ICD-9 code of 174.xx), lung cancer (162.xx), or multiple myeloma (203.0x) and had at least two diagnoses of bone metastases (198.5x) after the first diagnosis of cancer. In addition, individuals were required to have at least one SRE (based upon a previously published algorithm) on or after their initial diagnosis of bone metastases (their index date). Individuals were required to be continuously insured for at least 6 months prior to, and at least one month post their index date. Data were analyzed until 03/31/2005 or until the end of their continuous coverage, whichever occurred first. Descriptive statistics for each of these cohorts are provided. Results: A total of 1,204 individuals with breast cancer, 1,094 with lung cancer, and 258 with multiple myeloma were included in the study. The vast majority of individuals with breast cancer (96.5%), lung cancer (95.9%), or multiple myeloma (96.8%) were hospitalized. All three patient groups were likely to have SRE-related hospitalizations; multiple myeloma 43.4%, breast cancer 36.2% and lung cancer 35.6%. The average number of days per patient year that patients were hospitalized related to a diagnosis or procedure for a SRE was 6.75 days for patients with lung cancer, 6.56 days for patients with multiple myeloma, and 3.75 days for patients with breast cancer. Conclusion: Hospitalizations related to SREs are common and the number of days per year is substantial. No significant financial relationships to disclose.
Collapse
|
41
|
Cho Y, Chae Y, Kim J, Shon S, Moon J, Jeon S, Park J, Lee I, Lee I, Choi G, Jun S. Vascular endothelial growth factor gene polymorphisms and risk of colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4123 Background: Angiogenesis is closely related to the development, growth, and metastasis of solid tumors, including colorectal cancer (CRC), and the vascular endothelial growth factor (VEGF) is known to be a potent pro-angiogenic factor. Accordingly, the present study was conducted to evaluate the potential association between two VEGF polymorphisms (+405G > C, and 936C > T) and the risk of CRC. Methods: The VEGF genotypes were determined using fresh colorectal tumor tissue from 477 patients with CRC who underwent surgical resection and peripheral blood lymphocytes from 413 healthy controls based on a polymerase chain reaction/denaturing high-performance liquid chromatography (PCR/DHPLC) assay. The incidence of genotypes and haplotypes of two VEGF polymorphisms was compared between the patients with CRC and the controls. Results: The distribution of genotypes and allele frequencies of the 936C > T polymorphism in the CRC group did not differ from those in the control group. However, compared with the combined GC and CC genotype, the GG genotype of +405G > C polymorphism was significantly associated with an increased risk of CRC [odds ratio (OR), 1.575; 95% confidence interval (CI), 1.178–2.104; P = 0.002]. In the haplotype analyses, haplotype +405G / 936C was also associated with a significantly increased risk of CRC (OR, 1.264; 95% CI, 1.043–1.531; P = 0.017), whereas haplotype +405C / 936C was associated with a decreased risk of CRC (OR, 0.818; 95% CI, 0.677–0.989; P = 0.038). None of the VEGF polymorphisms studied significantly influenced the clinical or pathologic features of CRC. Conclusions: These findings suggest that the VEGF +405G > C polymorphism may be associated with the risk of CRC in the Korean population. No significant financial relationships to disclose.
Collapse
|
42
|
Chae Y, Kim J, Sohn S, Cho Y, Moon J, Jeon S, Park J, Lee I, Choi G, Jun S. Vascular endothelial growth factor (VEGF) gene polymorphisms associated with prognosis for patients with colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4125 Background: Vascular endothelial growth factor (VEGF) or its family may be considered to play an important role in lymphangiogenesis and lymphatic tumor spread, thereby affecting prognosis of colorectal cancer. Accordingly, the present study analyzed VEGF gene polymorphisms and their impact on the prognosis for patients with colorectal cancer. Patients and Methods: Four hundred and sixty-five consecutive patients with surgically treated colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tumor tissue and 3 VEGF (-2578C > A, -634G > C, and +936C > T) gene polymorphisms determined using a PCR/DHPLC (Polymerase chain reaction/Denaturing high-performance liquid chromatography) assay. Results: The median age of the patients was 64 years (range, 21–89), and 264 (56.7%) patients had colon cancer and 201 (48.2%) patients rectal cancer. Pathologic stages evaluable (n=464) after surgery were as follows: stage I (n=79, 17.0%), stage II (n=157, 33.8%), stage III (n=157, 33.8%), and stage IV (n=71, 15.3%). Multivariate survival analysis including stage, differentiation, and CEA level showed that survival for patients with the -634CC (overall survival [OS]: hazard ratio [HR]=0.175, P<0.001; progression-free survival [PFS]: HR=0.554, P=0.040) or GC genotype (OS: HR=0.158, P<0.001; PFS: HR=0.630, P=0.044) were better than for patients with the -634GG genotype, whereas the +936TT (OS: HR=65.959, P<0.001; PFS: HR=2.823, P=0.016) or CT genotype (OS: HR=16.116, P<0.001; PFS: HR=3.507, P<0.001) were associated with a worse survival compared to the CC genotype. In haplotype analysis, the -2578A/-634G/+936T haplotype exhibited a significantly worse survival when compared to the wild -2578C/-634G/+936C haplotype (OS: HR=4.670, P<0.001; PFS: HR=3.624, P<0.001). Conclusions: VEGF gene polymorphisms were found to be an independent prognostic marker for patients with colorectal cancer. Accordingly, the analysis of VEGF gene polymorphisms can help identify patient subgroups at high risk of a poor disease outcome. No significant financial relationships to disclose.
Collapse
|
43
|
Joyce AT, Harrison DJ, Jun S, Feliu AL, Anthony M. Risk of renal failure associated with IV bisphosphonate use in patients with multiple myeloma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8104 Background: IV Bisphosphonates including zoledronic acid (ZA) and pamidroniate are frequently used to delay time to skeletal related events in patients with multiple myeloma. The risk of renal toxicity with these agents is well known and regular monitoring of kidney function is required. Despite regular monitoring of creatinine, patients taking IV bisphosphonates may experience decreased renal functioning and renal failure. The purpose of this study was to determine the relative risk of renal failure in patients with multiple myeloma treated with ZA or pamidronate relative to patients whose lytic lesions remained untreated with medications. Methods: Commercially insured adults newly diagnosed with multiple myeloma 7/1/2002–6/2006 were identified using ICD-9 codes within the PHARMetrics Integrated Outcomes Database. Patients were stratified based on evidence of IV bisphosphonate use (treated) or no such evidence (untreated) following initial qualifying diagnosis. For treated patients, the date of first administration of an IV bisphosphonate was the patient's index date. Treated patients were matched to untreated patients based on use of radiation therapy or chemotherapy, year of cancer diagnosis, and health plan enrollment duration.The incidence rate (IR) for renal failure defined using ICD-9 codes was based on number of incident cases identified among the total person-years at risk and expressed as a rate per patient year. IRs and incidence rate ratios (IRR) (comparing the treated to untreated cohorts), with corresponding 95% confidence intervals are reported. Results: Treated (n=401) and untreated (n=431) patients were similar with respect to age (mean 56 years in both cohorts), but treated patients were more likely to be female (54% vs. 47%; p = 0.04) and less likely to have a history of anemia (48% vs. 51%; p=0.002). IV bisphosphonate use was associated with an 8.5% incidence of developing renal failure per patient year versus 4.9% in the untreated cohort (IRR 1.72; 95% CI 1.22–2.42). The risk was similar whether patients were treated with ZA or pamidronate. Conclusions: IV bisphosphonate use was associated with a significantly increased risk (72%) of developing renal failure in patients with multiple myeloma. No significant financial relationships to disclose.
Collapse
|
44
|
|
45
|
Lipton A, Alvarado C, De Boer R, Steger GG, Tonkin KS, Kinsey A, Fan M, Jun S. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.512] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
512 Background: Receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation, function, and survival. Denosumab, a fully human monoclonal antibody, binds and inhibits RANKL, thus suppressing excess osteoclastic activity associated with bone metastases. We report interim efficacy and safety results of an ongoing, phase 2 study of denosumab in IV BP treatment-naïve women with advanced breast cancer and bone metastases (BM). Methods: Eligible patients (pts; age ≥ 18 yrs with breast cancer; confirmed BM; naive to IV BP therapy) were stratified by chemo- or hormonal therapy and randomized to 1 of 6 cohorts (5 denosumab [double blind]; 1 IV BP [open label]; see table ). The primary endpoint was the % change from baseline (BL) to week 13 in the resorption marker, urinary N-telopeptide (uNTx), corrected for creatinine. Also evaluated were % of pts with ≥ 65% decrease in uNTX from BL, time to a 65% reduction in uNTx, % of pts with ≥ 1 skeletal-related event (SRE), and safety. Results: In total, 255 pts (∼40/cohort) were enrolled. Mean age was 57 to 59 yrs (denosumab cohorts) vs 52 yrs (BP). Most pts had > 2 sites of BM (denosumab, 74%; BP, 81%); 51% and 49% received concurrent chemo- or hormonal therapy, respectively. As shown in the efficacy table , the 120 mg Q4W dose resulted in the greatest % decrease from BL in uNTx. At data cutoff, the % of all denosumab pts with ≥ 1 SRE was 9% (20/212) vs 16% (7/43) of BP pts. Commonly reported adverse events (AE) among all pts included nausea, vomiting, asthenia, diarrhea, and bone pain. Of 198 denosumab pts tested, none developed anti-denosumab antibodies. Conclusion: In this interim analysis, denosumab resulted in rapid and sustained suppression of bone turnover and was at least as effective as IV BP at reducing the risk of SREs, with a safety profile similar to that seen in advanced breast cancer pts receiving cancer treatment. [Table: see text] [Table: see text]
Collapse
|
46
|
Suarez T, Fizazi K, Rahim Y, Wilson J, Fan M, Jun S, Lipton A. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8562] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8562 Background: Pts on established (≥ 8 weeks) IV BP who have elevated bone resorption markers, especially urinary N-telopeptide (uNTx), are at increased risk for skeletal related events (Coleman, J Clin Oncol 2005). Denosumab, a fully human monoclonal antibody, inhibits osteoclastic bone resorption by binding and neutralizing RANK ligand, a key mediator of osteoclast differentiation and function. Denosumab efficacy and safety were evaluated in a phase 2, randomized, open label, active-controlled study in advanced cancer pts with BM and elevated levels of uNTX despite established IV BP therapy. We report preliminary results from an interim analysis of 49 pts at week 13. Methods: Eligible pts (≥18 yrs old with solid tumor [except lung] or multiple myeloma [MM]; confirmed BM; screening uNTx > 50 nM BCE/mM creatinine [Cr]; on IV BP for ≥ 8 weeks before randomization) are stratified by baseline uNTx (50–100, >100) and tumor type. Pts are randomized to 1 of 3 arms: IV BP every 4 weeks (Q4W) or 180 mg denosumab given subcutaneously Q4W or Q12W. The primary endpoint is the proportion (%) of pts with uNTx < 50 nM BCE/mM Cr at week 13. Enrollment is ongoing (planned N = 135). Results: The mean (range) age of all pts in the analysis (33 denosumab; 16 BP) was 62.5 (39, 81) yrs; 96% had > 2 BM. The median time on prior IV BP (mostly zoledronic acid) was 5.1 months. Tumors included prostate (n = 24), breast (n = 20), other/MM (n = 5). The % of pts with uNTx < 50 nM BCE/mM Cr at week 13 was greater with denosumab (pooled arms) than IV BP: 76% (95% CI: 60.3, 91.2) vs 38% (95% CI: 18.5, 61.4; P = .015 Cochran-Mantel-Haenzel), respectively. No treatment-related serious adverse events (SAEs) were reported. Commonly reported AEs in the denosumab arms included nausea, peripheral edema, anemia, bone pain, and constipation. At data cutoff, 10 deaths (6/33 denosumab, 4/16 BP) had occurred on-study. Conclusions: These interim data suggest that denosumab normalizes uNTx more frequently than IV BP in pts with elevated uNTx despite 8 weeks of IV BP, across all tumor types. The AE profile of denosumab appeared similar to that of cancer pts undergoing treatment. [Table: see text]
Collapse
|
47
|
Acosta D, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Calafiura P, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'agnello S, Dell'orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman J, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garcia-Sciveres M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Griffiths M, Grosso-Pilcher C, Guenther M, Guimaraes da Costa J, Haber C, Hahn K, Hahn SR, Halkiadakis E, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, Ncnulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schemitz P, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Volobouev I, von der Mey M, Wagner P, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. Measurement of partial widths and search for direct CP violation in D0 meson decays to K-K+ and pi-pi+. PHYSICAL REVIEW LETTERS 2005; 94:122001. [PMID: 15903906 DOI: 10.1103/physrevlett.94.122001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2004] [Indexed: 05/02/2023]
Abstract
We present a measurement of relative partial widths and decay rate CP asymmetries in K-K+ and pi(-)pi(+) decays of D0 mesons produced in pp collisions at sqrt[s]=1.96 TeV. We use a sample of 2x10(5) D(*+)-->D0pi(+) (and charge conjugate) decays with the D0 decaying to K-pi(+), K-K+, and pi(-)pi(+), corresponding to 123 pb(-1) of data collected by the Collider Detector at Fermilab II experiment at the Fermilab Tevatron collider. No significant direct CP violation is observed. We measure Gamma(D0-->K-K+)/Gamma(D0-->K-pi(+))=0.0992+/-0.0011+/-0.0012, Gamma(D0-->pi(-)pi(+))/Gamma(D0-->K-pi(+))=0.035 94+/-0.000 54+/-0.000 40, A(CP)(K-K+)=(2.0+/-1.2+/-0.6)%, and A(CP)(pi(-)pi(+))=(1.0+/-1.3+/-0.6)%, where, in all cases, the first uncertainty is statistical and the second is systematic.
Collapse
|
48
|
Acosta D, Adelman J, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Ben-Haim E, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'Agnello S, Dell'Orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman JC, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Griffiths M, Grosso-Pilcher C, Grundler U, Guenther M, da Costa JG, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Lefevre R, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, NcNulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palencia E, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Sabik S, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Tourneur S, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veszpremi V, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Vollrath I, Volobouev I, von der Mey M, Wagner P, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. Search for excited and exotic electrons in the egamma decay channel in pp collisions at sqrt[s] = 1.96 TeV. PHYSICAL REVIEW LETTERS 2005; 94:101802. [PMID: 15783472 DOI: 10.1103/physrevlett.94.101802] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2004] [Indexed: 05/24/2023]
Abstract
We present a search for excited and exotic electrons (e(*)) decaying to an electron and a photon, both with high transverse momentum. We use 202 pb(-1) of data collected in pp collisions at sqrt[s] = 1.96 TeV with the Collider Detector at Fermilab II detector. No signal above standard model expectation is seen for associated ee(*) production. We discuss the e(*) sensitivity in the parameter space of the excited electron mass M(e(*)) and the compositeness energy scale Lambda. In the contact interaction model, we exclude 132 GeV/c(2)<M(e(*))<879 GeV/c(2) for Lambda = M(e(*)) at 95% confidence level (C.L.). In the gauge-mediated model, we exclude 126 GeV/c(2) < M(e(*)) < 430 GeV/c(2) at 95% C.L. for the phenomenological coupling f/Lambda approximately 10(-2) GeV-1.
Collapse
|
49
|
Acosta D, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Calafiura P, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'Agnello S, Dell'Orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman J, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garcia-Sciveres M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Grosso-Pilcher C, Guenther M, Guimaraes da Costa J, Haber C, Hahn K, Hahn SR, Halkiadakis E, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, Ncnulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Moulik T, Movilla Fernandez PA, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schemitz P, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Volobouev I, von der Mey M, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. First measurements of inclusive W and Z cross sections from run II of the fermilab tevatron collider. PHYSICAL REVIEW LETTERS 2005; 94:091803. [PMID: 15783955 DOI: 10.1103/physrevlett.94.091803] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2004] [Indexed: 05/24/2023]
Abstract
We report the first measurements of inclusive W and Z cross sections times leptonic branching ratios for pp collisions at square root[s]=1.96 TeV, based on their decays to electrons and muons. The data correspond to an integrated luminosity of 72 pb(-1) recorded with the CDF detector at the Fermilab Tevatron. We test e-mu universality in W decays, and we measure the ratio of leptonic W and Z rates from which the leptonic branching fraction B(W-->lnu) can be extracted as well as an indirect value for the total width of the W and the Cabibbo-Kobayashi-Maskawa matrix element, |V(cs)|.
Collapse
|
50
|
Jun S, Hong Y, Imamura H, Ha BY, Bechhoefer J, Chen P. Self-assembly of the ionic peptide EAK16: the effect of charge distributions on self-assembly. Biophys J 2005; 87:1249-59. [PMID: 15298927 PMCID: PMC1304463 DOI: 10.1529/biophysj.103.038166] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Amphiphilic peptides suspended in aqueous solution display a rich set of aggregation behavior. Molecular-level studies of relatively simple amphiphilic molecules under controlled conditions are an essential step toward a better understanding of self-assembly phenomena of naturally occurring peptides/proteins. Here, we study the influence of molecular architecture and interactions on the self-assembly of model peptides (EAK16s), using both experimental and theoretical approaches. Three different types of EAK16 were studied: EAK16-I, -II, and -IV, which have the same amino acid composition but different amino acid sequences. Atomic force microscopy confirms that EAK16-I and -II form fibrillar assemblies, whereas EAK16-IV forms globular structures. The Fourier transform infrared spectrum of EAK16-IV indicates the possible formation of a beta-turn structure, which is not found in EAK16-I and -II. Our theoretical and numerical studies suggest the underlying mechanism behind these observations. We show that the hairpin structure is energetically stable for EAK16-IV, whereas the chain entropy of EAK16-I and -II favors relatively stretched conformations. Our combined experimental and theoretical approaches provide a clear picture of the interplay between single-chain properties, as determined by peptide sequences (or charge distributions), and the emerging structure at the nano (or more coarse-grained) level.
Collapse
|